Reza Zadno, President and CEO of PROCEPT BioRobotics Corp (PRCT, Financial), executed a sale of 26,420 shares of the company on November 13, 2024. The transaction was filed on SEC Filing. Following this transaction, the insider now owns 232,025 shares of the company.
PROCEPT BioRobotics Corp is a medical device company that focuses on the design, development, and commercialization of robotic surgical devices. The company's main product, AquaBeam Robotic System, utilizes a proprietary waterjet technology to treat benign prostatic hyperplasia (BPH).
Over the past year, Reza Zadno has sold a total of 329,451 shares and has not made any purchases. The insider transaction history for PROCEPT BioRobotics Corp shows a total of 30 insider sells and no insider buys over the past year.
Shares of PROCEPT BioRobotics Corp were trading at $94.08 on the day of the transaction. The company has a market cap of approximately $4.812 billion.
The stock is currently considered Fairly Valued with a price-to-GF Value ratio of 1.14, based on a GF Value of $82.47. The GF Value is calculated considering historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
